Coherus Oncology (CHRS) Accumulated Expenses (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Accumulated Expenses data on file, last reported at $15.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 23.8% year-over-year to $15.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (down 23.8% YoY), and the FY2025 full-year result was $20.4 million, down 66.11% from the prior year.
• Accumulated Expenses retreated to $15.2 million in Q1 2026, from $20.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $115.7 million in Q1 2024 to a low of $11.0 million in Q2 2025.
• A 5-year average of $43.2 million and a median of $41.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 831.47% in 2024 and slumped 82.76% in 2025, its largest moves.
• Tracing CHRS's Accumulated Expenses over 5 years: stood at $50.1 million in 2022, then soared by 110.36% to $105.4 million in 2023, then plunged by 42.79% to $60.3 million in 2024, then sank by 66.11% to $20.4 million in 2025, then slipped by 25.59% to $15.2 million in 2026.
• Business Quant data shows CHRS's Accumulated Expenses at $15.2 million in Q1 2026, $20.4 million in Q4 2025, and $13.1 million in Q3 2025.